DEERFIELD, Ill., July 18, 2025--(BUSINESS WIRE)--TerSera Therapeutics LLC, a biopharmaceutical company with a focus in oncology, rare disease, and non-opioid pain management, announced today that its ...
Adeno-associated viral vector 9 (AAV9) has recently been shown to penetrate the blood–brain barrier via intravascular administration, making it a good candidate for diffuse gene delivery. However, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback